골밀도가 낮은 폐경 전 여성에서 알렌드로네이트 1년간 투여 후 골밀도 변화
Change of Bone Mineral Density after One-year Alendronate Treatment in Premenopausal Women with Low Bone Density
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives: To evaluate the efficacy of alendronate for premenopausal women with low bone density not resulted from secondary causes. Materials and Methods: Forty thee women who was diagnosed low bone mineral density (BMD) before menopause were included. All patients were evaluated by history taking, physical examination, and laboratory investigation to rule out underlying secondary causes of osteoporosis. They were randomized into two groups: Group I was administered oral alendronate 70 mg per week and Group II was not. All the participants received calcium carbonate 1,250 mg and cholecalciferol 1,000 IU daily. Bone mineral density by dual energy X-ray absorptiometry was measured before and after 1 year of treatment. Results: At baseline, there were no significant differences among the two groups in patient’s age, body mass index (BMI), and BMD. After 1 year of treatment, Group I showed significant increase in BMD. Conclusions: In premenopausal women with low BMD in the absence of secondary causes for osteoporosis, alendronate treatment for 1 year may increase BMD. We suggest that management of low bone density in the premenopausal women without secondary causes should be considered.
Abstract
Objectives: To evaluate the efficacy of alendronate for premenopausal women with low bone density not resulted from secondary causes. Materials and Methods: Forty thee women who was diagnosed low bone mineral density (BMD) before menopause were included. All patients were evaluated by history taking, physical examination, and laboratory investigation to rule out underlying secondary causes of osteoporosis. They were randomized into two groups: Group I was administered oral alendronate 70 mg per week and Group II was not. All the participants received calcium carbonate 1,250 mg and cholecalciferol 1,000 IU daily. Bone mineral density by dual energy X-ray absorptiometry was measured before and after 1 year of treatment. Results: At baseline, there were no significant differences among the two groups in patient’s age, body mass index (BMI), and BMD. After 1 year of treatment, Group I showed significant increase in BMD. Conclusions: In premenopausal women with low BMD in the absence of secondary causes for osteoporosis, alendronate treatment for 1 year may increase BMD. We suggest that management of low bone density in the premenopausal women without secondary causes should be considered.
참고문헌 (23)
- Bjarnason NH, "Number of years since menopause: spontaneous bone loss is dependent but response to hormone replacement therapy is independent", Bone, 30, pp.637~642 (2002)
- Christiansen C, "Estrogens, bone loss and preservation", Osteoporos Int, 1, pp.7~13 (1990)
- Shin JC, "A Statistical Analysis of Risk Factors for Osteoporosis in Menopausal Women", Korean J Obstet Gynecol, 41, pp.798~806 (1998)
- 김슬기, "광주 지역 여성의 연령에 따른 골밀도 변화", OSTEOPOROSIS, 8(2), pp.203~210 (2010), 대한골다공증학회
- Writing Group for the ISCD Position Development Conference, "Diagnosis of osteoporosis in men, premenopausal women, and children", J Clin Densitom, 7, pp.17~26 (2004)
- Lewieecki EM, "Special report on the official positions of the International Society for Clinical Densitometry", Osteoporos Int, 15, pp.779~784 (2004)
- Kelman A, "The management of secondary osteoporosis", Best Pract Res Clin Rheumatol, 19, pp.1021~1037 (2005)
- Fleisch N, "Effect of pyrophosphonate on hydroxyapatitie and its implications in calcium homeostasis", Nature, 212, pp.901~903 (1966)
- Haeney RP, "Calcium nutrition and bone health in the eldery", Am J Clin Nurt, 36, pp.986~1013 (1982)
- Assessment of fracture risk and its application to screening for postmenopausal osteoporosis, "WHO study group", WHO, ~, pp.WHO Technical Report Series 1994; 843 (1994)
- Peris P, "Aetiology and presenting symptoms in male osteoporis", Br J Rhematol, 34, pp.936~941 (1995)
- Peris P, "Clinical characteristics and etiologic factors of premenopausal steoporosis in a group of Spanish women", Semin Arthritis Rheum, 32, pp.64~70 (2002)
- Peris P, "Aetiology and clinical characteristics of male osteoporosis. Have they changed in the last few years?", Clin Exp Rheumatol, 26, pp.582~588 (2008)
- Khosla S, "Epidemiology and clinical features of osteoporosis in young individuals", Bone, 15, pp.551~555 (1994)
- Cohen A, "Clinical characteristics and medication use among premenopausal women with osteoporosis and low BMD:the experience of an osteoporosis referral center", J Womens Health (Larchmt), 18, pp.79~84 (2009)
- Peris P, "Clinical characteristics and etiologic factors of premenopausal osteoporosis in a group of Spanish women", Semin Arthritis Rheum, 32, pp.64~70 (2002)
- Kanis JA, "The diagnosis of osteoporosis", J Bone Miner Res, 9, pp.1137~1141 (1994)
- Kim SJ, "A Study on the establishment of reference range of osteoporosis at distal radius: A community-based study", Osteoporosis, 4, pp.98~106 (2006)
- Bhalla AK., "Management of osteoporosis in premenopausal woman", Best Pract Res Clin Rheumatol, 24, pp.313~327 (2010)
- 주일우, "Alendronate 10 mg을 2년간 투여한 한국 폐경 여성에서의 혈청 지질 수치 변화 -대조군 비교 연구-", Endocrinology and Metabolism, 22(1), pp.19~25 (2007), 대한내분비학회
- Minsker DH, "Effects of the bisphosphonate, alendronate on parturition in the rat", Toxicol Appl Pharmacol, 121, pp.217~223 (1993)
- Levy S, "Pregnancy outcome following in utero exposure to bisphosphonate", Bone, 44, pp.428~430 (2009)
- Ornoy A., "The outcome of pregnancy following pre-pregnancy or early pregnancy alendorante treatment", Reprod Toxicol, 22, pp.578~579 (2006)